Protocols

Ablynx grabs a €15M milestones payment from Merck KGaA; EyeGate surges on Valeant payout

→ Belgium’s Ablynx has teed up one of its Nanobodies for osteoarthritis for Merck KGaA. The German company accepted it and will now take it into the clinic, triggering a €15 million milestone payment.

→ JDRF says it will support ViaCyte’s work on a Type 1 diabetes program.

→ Shares of EyeGate Pharmaceuticals $EYEG jumped on the news that it has grabbed a development milestone from Valeant for its pact covering the EyeGate II Delivery System and EGP-437 combination product for post-operative ocular inflammation and pain in ocular surgery patients.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->